Core Insights - Zonsen PepLib Biotech Inc. has entered into a worldwide license agreement with Novartis for a peptide-based asset in radioligand therapies, granting Novartis exclusive rights for development and commercialization [1][2][3] Company Overview - Zonsen PepLib Biotech Inc. is an innovative biotechnology company focused on discovering and developing novel peptide-based therapeutics to improve treatment options globally, founded in September 2017 and headquartered in Zhuzhou, China [4] - The company employs over 200 people, with more than 80% engaged in research and development [4] Asset Development - The peptide asset has been developed internally by PepLib and is expected to complement Novartis' existing radioligand therapy portfolio, leveraging Novartis' capabilities to potentially provide new treatment options for patients [2][3] - Under the agreement, PepLib will receive an upfront payment of USD 50 million, with additional potential payments tied to development, regulatory, and sales milestones, as well as tiered royalties on future global net sales [3] Therapeutic Focus - PepLib has established a diverse suite of proprietary peptide libraries and discovery capabilities, primarily focusing on oncology and cardiometabolic diseases [5] - The company's platforms support multiple peptide-based modalities, including peptide radionuclide conjugates, peptide oligonucleotide conjugates, and peptide drug conjugates [5]

Core Insights - Altimmune, Inc. has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer to lead the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - Dr. Arbet-Engels brings over 30 years of experience in clinical development, regulatory approvals, and commercial launches, which will be crucial for advancing pemvidutide [2] - The company aims to establish a new standard of care in treating hepato-metabolic disorders, with upcoming data from the IMPACT trial and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [6] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [6] Leadership Transition - Dr. Scott Harris, the previous Chief Medical Officer, will retire but remain as a Senior Strategic Advisor until February 2026 [1][2] - Dr. Arbet-Engels has previously held senior roles at X4 Pharmaceuticals, Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, contributing to successful regulatory processes and clinical programs [2] Inducement Grant Details - Dr. Arbet-Engels will receive options to purchase 450,000 shares and 150,000 restricted stock units (RSUs) as part of his compensation package [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [4][5] - The RSUs will also vest over four years, with one-fourth vesting on the one-year anniversary and the remainder in three equal installments [5]

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [1] - The company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [1] Investor Engagement - Management will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 5, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025 [3] - The Morgan Stanley Global Healthcare Conference is scheduled for September 10, 2025, where a fireside chat will take place [3] - These events will include one-on-one meetings and webcasts accessible via the Altimmune website [3]

Core Points - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [3] - The company will report its second quarter 2025 financial results on August 12, 2025, and will host a conference call at 8:30 am E.T. to discuss these results and provide a business update [1] - The lead program of Altimmune is pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [3] Company Information - Altimmune is engaged in the development of therapeutics specifically targeting liver and cardiometabolic diseases [3] - The company’s lead therapeutic candidate, pemvidutide, is designed to address multiple conditions related to metabolic dysfunction and alcohol use [3] - For further information, Altimmune maintains an Investor Relations website where financial results and updates can be accessed [1][2]